Background: The increasing popularity of herbal medicines and dietary supplements has raised concern about potential adulteration with pharmaceutical drugs.
Objective: To detect and determine cyproheptadine (CYP) and dexamethasone (DEX) as adulterants in weight gain herbal supplements found in the Iraqi market.
Methods: Nine herbal supplements marketed as natural weight gainers were purchased from local pharmacies and were screened using high-performance liquid chromatography (HPLC) for qualitative and quantitative detection of CYP and DEX.
Objective: Originator pharmaceutical companies prolonging the patent of a medicine prevents rivals' entry to the market and competition. As the entry of generic alternatives usually results in price reduction, any delay in their entry potentially deprives the National Health Service (NHS) of much-needed savings. This study estimates the potential cost savings lost to the NHS as a result of delayed entry of generic low-dose buprenorphine (LDTB) patches in England.
View Article and Find Full Text PDFObjective: To investigate UK healthcare professionals' perceptions and perspectives towards biosimilar infliximab, etanercept and insulin glargine and the potential barriers and facilitators to their prescribing.
Design: A cross-sectional qualitative study design was used.
Setting: Five hospitals within the West Midlands area in UK.